ABCC4 and cystic fibrosis: We showed that the MRP4 inhibitor, MK-571, enhanced the potentiation caused by ivacaftor of nasal epithelial cell cultures derived from CF patients heterozygous for the G551D mutation (i.e., G551D/E585X or G551D/2622+1G>A).